Over 48 million U.S. adults have high Lipoprotein(a) levels

Most are unaware of their elevated risk for heart attack

 

Lipoprotein(a), or Lp(a), is a special type of LDL-cholesterol (“bad cholesterol”) that is a major risk factor for atherosclerotic heart disease and stroke. 

High Lp(a), combined with being positive for pro-inflammatory IL-1 genetic patterns, is predictive of recurrent heart attacks

1 in every 5 people is at risk


20%

Adults with elevated Lp(a)


60%

Adults with genetic pattern for elevated IL-1


>400%

Increased risk of 2nd heart attack with elevated Lp(a) and positive IL-1 genetic pattern

Atherosclerotic cardiovascular disease (ASCVD) is a chronic inflammatory disease initiated primarily by oxidized blood lipids such as LDL-cholesterol and Lp(a). The inflammation develops in the walls of heart and brain arteries, limiting the flow of blood and potentially leading to heart attack or stroke.

 

 

 

 

 

 

Lp(a) plays a major role in the process, and IL‑1 related inflammation greatly enhances it’s effects.

IL-1 Genetic Patterns Translate Lp(a) Levels Into Cardiovascular Events

In patients with elevated Lp(a), recurrent cardiovascular events are conditional on pro-inflammatory IL-1 genetic patterns. Elevated Lp(a) has a causal role in atherosclerotic CVD supported by strong human genetic and epidemiological evidence. 40-60% of individuals, depending on ethnic/racial background, carry IL-1 genetic patterns that overproduce IL-1β.

Watch the presentation to learn more about the important clinical links between Lp(a), IL-1, and cardiovascular disease.

Lp(a) levels can’t be reduced by statins or diet modifications, but new therapeutics based on PCSK9 inhibitors have been developed by multiple pharmaceutical companies. These drugs have been shown to reduce Lp(a) levels by 25 to 30%.

Our patented IL-1 genetic risk test and expanded cardiovascular genetic panel are providing key insights into prevention and treatment of cardiovascular disease and the overarching problems of systemic inflammation.

Already, our IL-1 genetic tests have demonstrated the ability to predict drug responses in patient groups based on their genetic patterns.

 

If you would like more information, or would like to discuss partnering with Interleukin Genetics, please contact us.

References

Tsimikas et al: Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a). Journal of the American College of Cardiology, 2014.

Varvel et al: Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532, 359 Patients in the United States. Arterioscler Thromb Vasc Biol., 2016.

Tsimikas et al: Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. The New England Journal of Medicine, 2005.

Khera et al: Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk. Circulation, 2014.